Study of Pioglitazone in Sporadic Inclusion Body Myositis

• Register: ClinicalTrials.gov
• Last refreshed on: 18 January 2021
• Main ID: NCT03440034
• Date of registration: 14/11/2017
• Prospective Registration: Yes
• Primary sponsor: Johns Hopkins University
• Public title: Study of Pioglitazone in Sporadic Inclusion Body Myositis
• Scientific title: An Open-Label Pilot Study of Pioglitazone in Sporadic Inclusion Body Myositis
• Date of first enrolment: May 22, 2018
• Target sample size: 19
• Recruitment status: Completed
• URL: https://clinicaltrials.gov/show/NCT03440034
• Study type: Interventional
• Study design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Basic Science. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

United States

Contacts

• Name: Jemima Albayda, MD
• Affiliation: Johns Hopkins University

Key inclusion & exclusion criteria

Inclusion Criteria:

- Age = 50 years

- Diagnosis of sporadic inclusion body myositis (sIBM) based on the sIBM Diagnostic
Criteria established by the 2010 European Neuromuscular Center.

- Must be able to ambulate at least 20 feet, with or without the use of an assistive
device. Patients may not use another person, wall, or furniture for support.

- Must be able to rise from a chair without support from another person or device.

- Premenopausal women must have a negative serum pregnancy test prior to dosing with
study medication.

- Women of child-bearing potential and men must agree to use adequate contraception
(hormonal or barrier method of birth control; abstinence) prior to study entry and for
the duration of study participation.

Exclusion Criteria:

- A history of diabetes mellitus, or prior or concurrent treatment with any diabetes
therapy

- Use of chronic immunosuppressive therapy including corticosteroids or intravenous
immune globulin (IVIG) within the past 6 months.

- Use of Vitamin E supplements within the past 3 months

- Creatine kinase (CK) > 15x the upper limit of normal

- Any condition other than sIBM that causes significant muscle pain, muscle weakness,
muscle atrophy, or joint pain. This includes but is not limited to such neurologic and
neuromuscular diseases as polymyositis or dermatomyositis, myasthenia gravis,
amyotrophic lateral sclerosis, stroke, multiple sclerosis, epilepsy, muscular
dystrophy, fibromyalgia, rheumatoid arthritis, spinal cord injury or degenerative
disease of the spine. Osteoarthritis is not exclusionary unless it limits the
patient's ability to comply with study tasks. Patients with a history of a hip or
vertebral fracture within the past year or surgical hip or knee replacement within the
past six months will be excluded.

- Patients receiving any medications or substances that are inhibitors or inducers of
CYP2C8 are ineligible. These medications include but are not limited to Gemfibrozil,
Rifampin, and warfarin.

- Pregnant women

- History of cancer less than five years prior, other than local basal or squamous cell
cancer.

- Patient has any medical condition or laboratory finding during screening, which, in
the investigator's opinion may interfere with participation, confound the results, or
pose any additional risk to the patient.



Age minimum: 50 Years
Age maximum: N/A
Gender: All

Health Condition(s) or Problem(s) studied

Musculoskeletal Disease

Inclusion Body Myositis

Muscular Diseases

Neuromuscular Diseases

Myositis

Nervous System Diseases

Intervention(s)

Drug: Pioglitazone

Primary Outcome(s)

Change from baseline in Peroxisome proliferator-activated receptor gamma coactivator 1-alpha target gene expression [Time Frame: 4 weeks, 16 weeks, 32 weeks after baseline]

Secondary ID(s)

IRB00130996

Source(s) of Monetary Support

Please refer to primary and secondary sponsors